In the original article, there was a mistake in [**Table 2**](#T2){ref-type="table"} as published. The row headers of [**Table 2**](#T2){ref-type="table"} in the article are missing. The corrected [**Table 2**](#T2){ref-type="table"} appears below.

###### 

Characteristics of the clinical trials of iguratimod in combination for RA.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References   Study                         Participants           Number                                              Intervention                                                                                                                   Duration    Primary Outcomes
  ------------ ----------------------------- ---------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ----------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B102]      Randomized\                   Country : Japan\       Total: 252\                                         IGU+MTX group:\                                                                                                                52 weeks    ACR20 at week 52:IGU+MTX group was similar to that at week 24 (69.5%).(PLA/IGU)+MTX group, the switch to IGU treatment signficantly improved from 30.7% at week 24 to 72.1% at week 52.\
               double-blind\                 Site: multicenter      IGU+MTX group:165\                                  IGU 25mg Bid,MTX 6 or 8 mg Qw and folic acid 5mg Qw(0-52 weeks).\                                                                          ACR50, ACR70 at week 52: IGU+MTX group was significantly improved compared with the values at week 24.
               placebo-controlled trial                             (PLA/IGU)+MTX group: (Weeks 1-28):88\               (PLA/IGU)+MTX group:\                                                                                                                      
                                                                    (Weeks28--52):68                                    Pla tablets(1-28 weeks); MTX 6 or 8mg Qw and folic acid 5 mg QW(1-52 weeks);IGU 25mg Qd(28-32 weeks),25mg Bid (32-52 weeks).               

  [@B3]        Randomized double-blind\      Country : Japan\       Total: 252\                                         IGU group:164\                                                                                                                 24 weeks    ACR20 at week 24 was 69.5% in the IGU group compared with 30.7% in the placebo group (P \< 0.001). Significant improvements in the ACR50, ACR70.
               placebo-controlled trial      Site:multicenter       IGU group:164\                                      IGU 25mg Qd (0-4 weeks)\                                                                                                                   
                                                                    placebo group:88                                    25mg Bid (4-24 weeks).\                                                                                                                    
                                                                                                                        MTX 6 or 8mg Qw, folic acid 5mg Qw.\                                                                                                       
                                                                                                                        placebo group: MTX 6 or 8mg Qw and folic acid 5mg Qw,and placebo tablets                                                                   

  [@B101]      Prospective\                  Country : Japan\       Total: 131\                                         IGU group:25mg Bid(0-24 weeks)\                                                                                                24 weeks    ACR 20 and ACR 50 at 24 weeks: combination of IGU with MTX was\
               trial                         Site: Single-center    MTX+IGU group:44\                                   MTX group:10mg Qw (0-24 weeks)\                                                                                                            superior to IGU or MTX\
                                                                    IGU group:38\                                       MTX+IGU group: IGU 25mg Bid (0-24 weeks).MTX 10mg Qw (0-24 weeks)                                                                          monotherapy.
                                                                    MTX group:49                                                                                                                                                                                   

  [@B1]        Randomized controlled trial   Country : China\       Total: 60\                                          MTX+ IGU group: IGU 25mg Bid (0-24 weeks).MTX 10mg Qw (0-4 weeks),12.5mg Qw (4-24 weeks)\                                      24 weeks    ACR50 at 24 weeks:MTX+T-614 group showed statistically significant differences comparing with the MTX group (P \< 0.05).
                                             Site : Single-center   MTX+ IGU group:30\                                  MTX group: 10mg Qw (0-4 weeks),12.5mg Qw (4-24 weeks)                                                                                      
                                                                    MTX group:30                                                                                                                                                                                   

  [@B4]        Retrospective study           Country : Japan\       Total: 41\                                          IGU 25mg Qd (0-4 weeks), then increased to 25mg Bid based on the physician's discretion.                                       24 weeks    remission can be achieved by IGU addon in RA patients responding partially to 24-week or longer administration of bDMARD
                                             Site: Single-center    patients who showed an\                                                                                                                                                                        
                                                                    inadequate response to biological DMARDs                                                                                                                                                       

  [@B5]        Retrospective study           Country : China\       Total: 23\                                          MTX:12.5mg Qw\                                                                                                                 24 weeks    After 24 weeks:the RA patients showed a significant improvement in mean DAS28 score from baseline. 18 (78%), 15 (65%), and 12 (50%) patients, respectively, met the ACR20, ACR50, and ACR70 response criteria.
                                             Site : Single-center   patients who showed an\                             HCQ:0.1mg Bid\                                                                                                                             
                                                                    inadequate response to MTX--CsA--HCQ-- prednisone   CsA:50mg Bid\                                                                                                                              
                                                                                                                        Prednisone:7.5mg Qd\                                                                                                                       
                                                                                                                        IGU: 25mg Bid                                                                                                                              

  [@B2]        Retrospective study           Country: Japan\        Total: 31\                                          TCZ 162mg Q2w or 8 mg/kg Qm;IGU 25 mg Qd,then increased to 25mg Bid depending on physician's decision.                         24 weeks    Using the EULAR criteria, 64.5% achieved a moderate response, and 51.6% achieved ACR 20 at 24 weeks
                                             Site: multicenter      patients who showed an\                                                                                                                                                                        
                                                                    inadequate response to TCZ                                                                                                                                                                     

  [@B100]      Retrospective study           Country : Japan\       Total: 69\                                          IGU group:IGU 25mg Qd (0-4 weeks), then increased to 25mg Bid based on the physician's discretion.\                            36 months   The survival rate of IGU therapy at 3 years was 40.6%. The disease activity was significantly\
                                             Site:multicenter       IGU group:28\                                       MTX+IGU group: MTX was 8.5 ± 3.4 mg/week\                                                                                                  decreased in the IGU group and MTX plus IGU group compared with the baseline.
                                                                    MTX+IGU:28\                                         bDMARDs+IGU group: IFX/ETN/ADA/TCZ/ABT/GLM(n=1/4/3/1/2/2)                                                                                  
                                                                    bDMARDs+IGU:13                                                                                                                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
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